Breast Cancer
Conference Coverage
VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer
News
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancer
Key clinical point: Adjuvant capecitabine improves outcomes in women with HER2-negative breast cancer who have residual invasive disease after...
News
High risk for getting breast cancer linked with low risk of metastasis
Key clinical point: High risk of breast cancer based on specific prediction models was associated with favorable tumor prognosticators and reduced...
News
Die not yet cast for lymphazurin and methylene blue dye
Key clinical point: Contrary to prior studies, lymph node positivity was higher with lymphazurin than methylene blue in patients with early breast...
News
What’s anticipated at SABCS 2015?
Article
Annual screening mammography beginning at age 40 saves the most lives
If women wait until age 45 to begin annual screening, then shift to biennial screening at age 55, more than 38,000 women now in their 40s will die...
Conference Coverage
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
Among women diagnosed with breast cancer in their 70s, more will die from cardiovascular disease than from their malignancy.
News
Racial differences found in neoadjuvant chemo, pCR rates for breast cancer
Key clinical point: Non-white Hispanic, Asian, and black women are likelier to receive neoadjuvant chemotherapy than are white women for breast...
News
No benefit from dual anti-HER2 blockade in early breast cancer
Key clinical point: Adjuvant lapatinib and trastuzumab resulted in similar disease-free survival, compared with trastuzumab alone in early HER2-...
News
No racial disparity in appropriate use of Oncotype DX
Key clinical point: ODX testing is more likely to be administered to nonblack women with node-positive disease than to black women. Major finding...